Loracarbef Anhydrous

Loracarbef Anhydrous

SCHEMBL34153

N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CC[C@H]12)c1ccccc1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Loracarbef Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.66
ALDH1A1 P00352 7/20 0.66
HSD17B10 Q99714 7/20 0.66
MAPT P10636 6/20 0.66
KMT2A Q03164 6/20 0.66
TDP1 Q9NUW8 6/20 0.66
MEN1 O00255 5/20 0.66
HPGD P15428 4/20 0.66
CYP3A4 P08684 4/20 0.66
SLC15A2 Q16348 4/20 0.66
LMNA P02545 3/20 0.66
CYP2C9 P11712 2/20 0.66
NR1I2 O75469 1/20 0.66
ADORA3 P0DMS8 1/20 0.66
CTDSP1 Q9GZU7 1/20 0.66
HIF1A Q16665 1/20 0.66
BLM P54132 2/20 0.55
CYP2C19 P33261 1/20 0.55
MAPK1 P28482 1/20 0.55
ADRA1A P35348 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Loracarbef Anhydrous SCHEMBL1819705 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL9017047 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL12306378 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL235140 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL2453036 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL10692457 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL13457172 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL17530968 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL17530291 1.00 KDM4E (0.66) KDM4EALDH1A1HSD17B10MAPTKMT2A
Loracarbef Anhydrous SCHEMBL1229813 0.99 KDM4E (0.67) KDM4EALDH1A1HSD17B10MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 18333 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637481-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2026-05-26 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-20260027140-A1 COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA ATOPIC MEDICAL INC (US) 2026-01-29 US claimed
EP-4680203-A1 COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS Prolevi Bio AB (SE) 2026-01-21 EP claimed
EP-4658292-A1 PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PSEUDOMONAS INFECTIONS The Administrators of The Tulane Educational Fund (US) 2025-12-10 EP claimed
EP-4659014-A1 EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING President And Fellows Of Harvard College (US) 2025-12-10 EP claimed
US-12465623-B2 Use of parasites and extracellular vesicles obtained from parasites in cancer treatment YEDITEPE UNIVERSITESI (TR) 2025-11-11 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
WO-1996024684-A1 POTENTIATORS OF ANTIBACTERIAL AGENTS MICROCIDE PHARMACEUTICALS, INC. (US) 1996-08-15 WO claimed
EP-0680322-A1 PHARMACEUTICAL FORMULATIONS COMPRISING CLAVULANIC ACID ALONE OR IN COMBINATION WITH OTHER BETA-LACTAM ANTIBIOTICS SMITHKLINE BEECHAM PLC (GB) 1995-11-08 EP claimed
US-5409917-A Topical treatment of acne with cephalosporins Towsend, Marvin S. (US) 1995-04-25 US claimed
EP-0637587-A1 Bicyclic beta-lactam/paraben complexes ELI LILLY AND COMPANY (US) 1995-02-08 EP claimed
EP-0629625-A1 Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof ELI LILLY AND COMPANY (US) 1994-12-21 EP claimed
EP-0627431-A1 Process for preparing crystalline loracarbef monohydrate ELI LILLY AND COMPANY (US) 1994-12-07 EP claimed
US-5352782-A By steaming ELI LILLY AND COMPANY (US) 1994-10-04 US claimed
WO-1994016696-A1 PHARMACEUTICAL FORMULATIONS COMPRISING CLAVULANIC ACID ALONE OR IN COMBINATION WITH OTHER BETA-LACTAM ANTIBIOTICS SMITHKLINE BEECHAM PLC (GB) 1994-08-04 WO claimed
EP-0280571-B1 SUSTAINED RELEASE MATRIX FORMULATIONS ELI LILLY AND COMPANY (US) 1993-08-04 EP claimed
EP-0549264-A1 Purified para-nitrobenzyl esterase from bacillus OKLAHOMA STATE UNIVERSITY (US) 1993-06-30 EP claimed